Oral midazolam dose comparison combined with intranasal dexmedetomidine for procedural sedation in infants and toddlers

Phase 4, open-label trial of midazolam and dexmedetomidine in procedural sedation and analgesia (PSA) (2 arms), sponsored by Sichuan Provincial Maternal and Child Health Hospital. Primary endpoint: Success rate of procedural sedation within 30 minutes after drug administration. Planned start Mar 2025; status: not yet recruiting.